Pharmacology of testosterone replacement therapy preparations

Jennifer J Shoskes, Meghan K Wilson, Michael L Spinner, Jennifer J Shoskes, Meghan K Wilson, Michael L Spinner

Abstract

The goal of testosterone replacement therapy (TRT) is to return serum testosterone levels to within physiologic range and improve symptoms in hypogonadal men. Some of the symptoms aimed to improve upon include decreased libido, erectile dysfunction, infertility, hot flashes, depressed mood, and loss of muscle mass or hair. Clinical use of testosterone for replacement therapy began approximately 70 years ago. Over the decades, numerous preparations and formulations have been developed primarily focusing on different routes of delivery and thus pharmacokinetics (PKs). Currently the routes of delivery approved for use by the United States Food and Drug Administration encompasses buccal, nasal, subdermal, transdermal, and intramuscular (IM). Many factors must be considered when a clinician is choosing the most correct formulation for a patient. As this decision depends highly on the patient, active patient participation is important for effective selection. The aim of this review is to describe and compare all testosterone preparations currently available and approved by the United States Food and Drug Administration. Areas of focus will include pharmacology, PKs, adverse effects, and specifics related to individual delivery routes.

Keywords: Drug delivery systems; hypogonadism; pharmacology; testosterone.

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Molecular structure. (A) Testosterone; (B) 17α-methyltestosterone.
Figure 2
Figure 2
Molecular structure. (A) Testosterone undecanoate; (B) testosterone cypionate; (C) testosterone enanthate.

References

    1. United States Food and Drug Administration [Internet]. Silver Spring: United States Food and Drug Administration; 2016 [updated 2005 March 3; cited 2016 Apr 25]. Available online:
    1. Manni A, Pardridge WM, Cefalu W, et al. Bioavailability of albumin-bound testosterone. J Clin Endocrinol Metab 1985;61:705-10. 10.1210/jcem-61-4-705
    1. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-59. 10.1210/jc.2009-2354
    1. Araujo AB, O'Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004;89:5920-6. 10.1210/jc.2003-031719
    1. Baillargeon J, Urban RJ, Ottenbacher KJ, et al. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med 2013;173:1465-6. 10.1001/jamainternmed.2013.6895
    1. Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol 2011;165:675-85. 10.1530/EJE-11-0221
    1. Osterberg EC, Bernie AM, Ramasamy R. Risks of testosterone replacement therapy in men. Indian J Urol 2014;30:2-7. 10.4103/0970-1591.124197
    1. Velazquez I, Alter BP. Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions. Am J Hematol 2004;77:257-67. 10.1002/ajh.20183
    1. Delorimier AA, Gordan GS, Lowe RC, et al. Methyltestosterone, related steroids, and liver function. Arch Intern Med 1965;116:289-94. 10.1001/archinte.1965.03870020129023
    1. Daggett PR, Wheeler MJ, Nabarro JD. Oral testosterone, a reappraisal. Horm Res 1978;9:121-9. 10.1159/000178904
    1. Bagatell CJ, Bremner WJ. Androgen and progestagen effects on plasma lipids. Prog Cardiovasc Dis 1995;38:255-71. 10.1016/S0033-0620(95)80016-6
    1. Nieschlag E, Behre HM, Bouchard P, et al. Testosterone replacement therapy: current trends and future directions. Hum Reprod Update 2004;10:409-19. 10.1093/humupd/dmh035
    1. Yoshida EM, Erb SR, Scudamore CH, et al. Severe cholestasis and jaundice secondary to an esterified testosterone, a non-C17 alkylated anabolic steroid. J Clin Gastroenterol 1994;18:268-70. 10.1097/00004836-199404000-00036
    1. Striant® [package insert]. Chesterbrook (PA): Actient Pharmaceuticals LLC; May 2015.
    1. Dinsmore WW, Wyllie MG. The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men. BJU Int 2012;110:162-9. 10.1111/j.1464-410X.2011.10837.x
    1. Wang C, Swerdloff R, Kipnes M, et al. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab 2004;89:3821-9. 10.1210/jc.2003-031866
    1. Korbonits M, Slawik M, Cullen D, et al. A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males. J Clin Endocrinol Metab 2004;89:2039-43. 10.1210/jc.2003-030319
    1. Natesto™ [package insert]. Malvern (PA): Endo Pharmaceuticals; May 2015.
    1. Mattern C, Hoffmann C, Morley JE, et al. Testosterone supplementation for hypogonadal men by the nasal route. Aging Male 2008;11:171-8. 10.1080/13685530802351974
    1. Deansley R, Parkes AS. Further experiments on the administration of hormones by the subcutaneous implantation of tablets. Lancet 1938;2:606-9. 10.1016/S0140-6736(00)41059-7
    1. Behre HM, Wang CC, Handelsman DJ, et al. Pharmacology of testosterone preparations. Available online:
    1. Testopel® [package insert]. Malvern (PA): Auxilium Pharmaceuticals Inc.; May 2015.
    1. Handelsman DJ, Conway AJ, Boylan LM. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab 1990;71:216-22. 10.1210/jcem-71-1-216
    1. Androderm® [package insert]. Parsippany (NJ): Actavis; May 2015.
    1. Dobs AS, Meikle AW, Arver S, et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999;84:3469-78.
    1. Meikle AW, Mazer NA, Moellmer JF, et al. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab 1992;74:623-8.
    1. Abadilla KA, Dobs AS. Topical testosterone supplementation for the treatment of male hypogonadism. Drugs 2012;72:1591-603. 10.2165/11635620-000000000-00000
    1. AndroGel®, 1% [package insert]. North Chicago (IL): AbbVie; May 2015.
    1. AndroGel®, 1.62% [package insert]. North Chicago (IL): AbbVie; May 2015.
    1. Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000;85:4500-10.
    1. Fortesta® [package insert]. Malvern (PA): Endo Pharmaceuticals; May 2015.
    1. Dobs AS, McGettigan J, Norwood P, et al. A novel testosterone 2% gel for the treatment of hypogonadal males. J Androl 2012;33:601-7. 10.2164/jandrol.111.014308
    1. Testim® [package insert]. Malvern (PA): Auxilium Pharmaceuticals Inc.; September 2009.
    1. Marbury T, Hamill E, Bachand R, et al. Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim, compared to AndroGel. Biopharm Drug Dispos 2003;24:115-20. 10.1002/bdd.345
    1. Vogelxo® [package insert]. Maple Grove (MN): Upsher-Smith Laboratories; May 2015.
    1. Steidle C, Schwartz S, Jacoby K, et al. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003;88:2673-81. 10.1210/jc.2002-021058
    1. Axiron® [package insert]. Indianapolis (IN): Eli Lilly; May 2015.
    1. Wang C, Ilani N, Arver S, et al. Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men. Clin Endocrinol (Oxf) 2011;75:836-43. 10.1111/j.1365-2265.2011.04152.x
    1. Byrne M, Nieschlag E. Testosterone replacement therapy in male hypogonadism. J Endocrinol Invest 2003;26:481-9. 10.1007/BF03345206
    1. Edelstein D, Basaria S. Testosterone undecanoate in the treatment of male hypogonadism. Expert Opin Pharmacother 2010;11:2095-106. 10.1517/14656566.2010.505920
    1. Depo-Testosterone© [package insert]. New York (NY): Pharmacia and Upjohn Company; April 2015.
    1. Nankin HR. Hormone kinetics after intramuscular testosterone cypionate. Fertil Steril 1987;47:1004-9. 10.1016/S0015-0282(16)59237-1
    1. Testosterone enanthate [package insert]. Eatontown (NJ): West-Ward Pharmaceuticals; November 2015.
    1. Snyder PJ, Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 1980;51:1335-9. 10.1210/jcem-51-6-1335
    1. United States Food and Drug Administration Orange Book [Internet]. Silver Spring: United States Food and Drug Administration; 2016 [updated 2016 April; cited 2016 May 13]. Available online:
    1. Aveed© [package insert]. Malvern (PA): Endo Pharmaceuticals; May 2015.
    1. Wang C, Harnett M, Dobs AS, et al. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial. J Androl 2010;31:457-65. 10.2164/jandrol.109.009597

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit